Abstract: The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Chang, A.J.; DeSilva, R.; Jain, S.; Lears, K.; Rogers, B.; Lapi, S. 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals 2012, 5, 79-93.
Chang AJ, DeSilva R, Jain S, Lears K, Rogers B, Lapi S. 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals. 2012; 5(1):79-93.
Chang, Albert J.; DeSilva, Ravindra; Jain, Sandeep; Lears, Kimberley; Rogers, Buck; Lapi, Suzanne. 2012. "89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors." Pharmaceuticals 5, no. 1: 79-93.